The Vigabatrin REMS Program is needed by the FDA to make certain educated risk-benefit decisions before starting treatment, and to guarantee ideal use of vigabatrin while people are treated. When vision loss will occur, it is not feasible for your health care supplier to recognize.
It is advised that your healthcare provider examination your (or your youngster's) vision prior to or within 4 weeks after beginning SABRIL and at least every 3 months throughout therapy till SABRIL is quit. If you or your kid have any side effect that troubles you or that does not go away, inform your healthcare provider.
If you are pregnant or intend to get expecting, tell your health care supplier. If vision testing can not be done, your doctor might proceed prescribing SABRIL, yet will not have the ability to look for any vision loss. If vision examinations are refrained routinely, your healthcare provider might stop recommending SABRIL for you (or your kid).